Winner of 2009 Gerald A. Beathard Fellowship award announced

Lifeline Vascular Access(SM), the nation's leading provider of vascular access management services, today announced that Dr. Stephen Osaguona has been awarded the 2009 Gerald A. Beathard Fellowship in Interventional Nephrology. The fellowship is named for one of the foremost pioneers in Interventional Nephrology and Lifeline's Vice President of Provider Development, Dr. Gerald A. Beathard. It was made possible through an educational grant from MedComp(R) which awards one recipient with six months of specialized training for eventual certification in the field of Interventional Nephrology.

"Out of a deep and talented pool of highly qualified candidates, Dr. Stephen Osaguona stands out for his demonstration of character and the skills to be successful in Interventional Nephrology," said Gerald A. Beathard, M.D., Vice President of Provider Development at Lifeline Vascular Access. "I commend Dr. Osaguona and look forward to watching him build a successful career in Interventional Nephrology."

"I am honored to accept a fellowship named after Gerald Beathard," said Dr. Stephen Osaguona. "This fellowship offers a unique opportunity, and I thank Dr. Beathard and Lifeline Vascular Access for giving me the chance to learn from the best at a state-of-the-art managed facility. I believe every kidney patient deserves to have his or her vascular access managed by a trained nephrologist who knows him or her and the medical condition at issue, thus delivering excellent services."

In July, Dr. Osaguona will begin his fellowship training under the supervision of Dr. Linda Francisco at the Vascular Center of Wichita Nephrology, which performs more than 1,600 procedures annually with a 99% success rate and was named Center of the Year by Lifeline Vascular Access in 2007.

http://www.lifelinevascularaccess.com/

.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Spermidine regulates RIPK1 to combat diabetes and vascular damage